share_log

汇宇制药(688553.SH):注射用环磷酰胺获得美国FDA批准

Huiyu Pharmaceutical (688553.SH): Injectable cyclophosphamide has received approval from the FDA in the USA.

Gelonghui Finance ·  Dec 23, 2024 18:07

Gelonghui, December 23 | Huiyu Pharmaceutical (688553.SH) announced that the company recently received a notice of approval of the company's new injectable cyclophosphamide drug (ANDA). Cyclophosphamide for injection is an oncological drug, mainly used to treat chronic lymphocytic leukemia (CLL); acute lymphocytic leukemia (ALL); as a condition for bone marrow transplantation, treatment of acute lymphocytic leukemia, chronic lymphocytic leukemia, and acute myeloid leukemia; Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple Hodgkin lymphoma myeloma; metastasis Ovarian cancer and breast cancer; adjuvant treatment for breast cancer; Evan's sarcoma; small cell lung cancer; advanced or metastatic neuroblastoma; life-threatening autoimmune diseases: severe progressive lupus nephritis and Wegner's granulomatous disease.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment